Stay updated on Elranatamab Combo in Myeloma Clinical Trial
Sign up to get notified when there's something new on the Elranatamab Combo in Myeloma Clinical Trial page.

Latest updates to the Elranatamab Combo in Myeloma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page has removed information regarding heavy traffic affecting NLM-NCBI services and products, as well as links to contact information for Pfizer study centers.SummaryDifference1%
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check41 days agoChange DetectedThe study has added 64 new locations in Japan and updated its status to recruiting, while 74 previous locations have been removed, indicating a significant shift in the study's geographic focus and participant recruitment status.SummaryDifference5%
- Check55 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check62 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this aspect.SummaryDifference0.2%
- Check91 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to Elranatamab Combo in Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab Combo in Myeloma Clinical Trial page.